The forthcoming AD/PD™ meeting will take place as a hybrid conference in Gothenburg (Sweden) and online from 28 March to 1 April 2023. The AD/PD™ Conference offers a high-quality scientific program covering the most recent research, clinical trials, developments, and treatments in Alzheimer’s and Parkinson’s disease.
The AD/PD™ Conference has become the main event of the year in the field of neurodegenerative diseases, attracting leading medical and scientific professionals from around the world. AD/PD™ is now an annual meeting, with a continuing focus on the ADVANCES IN SCIENCE & THERAPY of Alzheimer’s and Parkinson’s Diseases and related neurological disorders.
Several AMYPAD researchers will be presenting their respective work at the upcoming AD/PD™ Conference:
- Lyduine Collij (VUmc) “Head-To-Head Comparison Between Baseline Semi- And Fully-Quantitative Amyloid-Pet Measures To Predict Changes In Cognition: The AMYPAD PNHS Study”
Saturday 1st April 2023, 12:40 – 12:55, Symposium PET 02, Hall G3
- Sophie E. Mastenbroek (VUmc) “Relationship Between A Continuous Amyloid CSF/PET Discordance Measure With Demographics And Longitudinal Cognition”
Saturday 1st April 2023, 14:45 – 15:00, Symposium: fluid biomarkers and imaging in AD, PD AND PSP, Hall G3
- Luigi Lorenzini (VUmc) “Cortical Amyloid Predicts Longitudinal Atrophy In Non Demented Individuals: Results From The AMYPAD Prognostic Study”
Saturday 1st April 2023, 18:55 – 19:10, Symposium: AD, PD, LBD, Biomarkers, Diagnosis, Imaging & Clinical Trials, Hall G4
- Emma Luckett (KU Leuven) “Weighted gene co-expression network analysis detects changes in the peripheral blood transcriptome in asymptomatic Alzheimer’s disease”
Wednesday 29 March 2023, 15-15-15:30, Symposium Genetics Neurodegeneration 02, Hall G2
- Ariane Bollack (UCL) “A Centiloid window to help predict true amyloid accumulation”
We are very much looking forward to the conference and discussing our work and results!
For more information about the event, please visit: https://adpd.kenes.com/